Cargando…

Cyclin-dependent kinase 6 (CDK6) is a candidate diagnostic biomarker for early non-small cell lung cancer

BACKGROUND: Cyclin-dependent kinase 6 (CDK6) is an important regulatory protein of the cell cycle and plays an important role in tumor progression. The aim of this study was to investigate the expression of CDK6 in T1 stage non-small cell lung cancer (NSCLC) and to explore the association of CDK6 wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Wangang, Wang, Lifang, Zheng, Zhiguo, Chen, Wenhu, Du, Peng, Zhao, Hongguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798208/ https://www.ncbi.nlm.nih.gov/pubmed/35117162 http://dx.doi.org/10.21037/tcr.2019.11.21

Ejemplares similares

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences
por: Johnston, Stephen, et al.
Publicado: (2023)

Cyclin-dependent kinase 6 (CDK6) as a potent regulator of the ovarian primordial-to-primary follicle transition
por: Ataei-Nazari, S., et al.
Publicado: (2022)

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
por: Finn, Richard S., et al.
Publicado: (2016)

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
por: Kang, Jian, et al.
Publicado: (2014)

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines
por: Coxon, Christopher R., et al.
Publicado: (2016)

The Role of Cyclin-Dependent Kinases (CDK) 4/6 in the Ovarian Tissue and the Possible Effects of Their Exogenous Inhibition
por: Scavone, Graziana, et al.
Publicado: (2023)

Predicting clinical benefit from continuation of cyclin dependent kinase (CDK) 4/6 inhibitors beyond progression
por: Foldi, Julia, et al.
Publicado: (2023)

Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
por: Thill, Marc, et al.
Publicado: (2018)

The Cyclin-dependent Kinase Cdk2 Regulates Thymocyte Apoptosis
por: Hakem, Anne, et al.
Publicado: (1999)

Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
por: Tavakolian, Shaian, et al.
Publicado: (2020)

Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review
por: Łukasik, Paweł, et al.
Publicado: (2021)

Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2021)

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
por: Yıldırım, Hasan Çağrı, et al.
Publicado: (2022)

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells
por: Ogata, Ryohei, et al.
Publicado: (2020)

Cyclin-dependent kinase 5 (CDK5) regulates the circadian clock
por: Brenna, Andrea, et al.
Publicado: (2019)

miR-148a-3p suppresses the progression of acute myeloid leukemia via targeting cyclin-dependent kinase 6 (CDK6)
por: Zhou, Hong, et al.
Publicado: (2021)

Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma
por: Matsumoto, M, et al.
Publicado: (1999)

Lineage specific composition of cyclin D–CDK4/CDK6–p27 complexes reveals distinct functions of CDK4, CDK6 and individual D‐type cyclins in differentiating cells of embryonic origin
por: Bryja, V., et al.
Publicado: (2008)

Deciphering the binding behavior of flavonoids to the cyclin dependent kinase 6/cyclin D complex
por: Zhang, Jingxiao, et al.
Publicado: (2018)

Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
por: Kryštof, Vladimír, et al.
Publicado: (2012)

Cyclin-dependent kinase 4/6 inhibition in cancer therapy
por: Johnson, Neil, et al.
Publicado: (2012)

Regulation of Sox6 by Cyclin Dependent Kinase 5 in Brain
por: Rudrabhatla, Parvathi, et al.
Publicado: (2014)

Nucleophosmin Phosphorylation by v-Cyclin-CDK6 Controls KSHV Latency
por: Sarek, Grzegorz, et al.
Publicado: (2010)

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
por: De Angelis, Claudia, et al.
Publicado: (2020)

The awakening of the CDK10/Cyclin M protein kinase
por: Guen, Vincent J., et al.
Publicado: (2017)

Exploring cyclin-dependent kinase inhibitors: a comprehensive study in search of CDK-6 inhibitors using a pharmacophore modelling and dynamics approach
por: Chagaleti, Bharath Kumar, et al.
Publicado: (2023)

mTORC1 Down-Regulates Cyclin-Dependent Kinase 8 (CDK8) and Cyclin C (CycC)
por: Feng, Daorong, et al.
Publicado: (2015)

Effects of the Cyclin-Dependent Kinase 10 (CDK10) on the Tamoxifen Sensitivity of Keloid Samples
por: Liu, Ying, et al.
Publicado: (2012)

An Integrative Human Pan-Cancer Analysis of Cyclin-Dependent Kinase 1 (CDK1)
por: Liu, Xuanyou, et al.
Publicado: (2022)

A Requirement for Cyclin D3–Cyclin-dependent Kinase (cdk)-4 Assembly in the Cyclic Adenosine Monophosphate–dependent Proliferation of Thyrocytes
por: Depoortere, Fabienne, et al.
Publicado: (1998)

Are all cyclin-dependent kinases 4/6 inhibitors created equal?
por: Marra, Antonio, et al.
Publicado: (2019)

The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer
por: Tanaka, Tomohito, et al.
Publicado: (2017)

Effect of pH on the structure and function of cyclin-dependent kinase 6
por: Yousuf, Mohd, et al.
Publicado: (2022)

Inhibiting Cyclin-Dependent Kinase 6 by Taurine: Implications in Anticancer Therapeutics
por: Yousuf, Mohd, et al.
Publicado: (2022)

Downregulation of microRNA-637 Increases Risk of Hypoxia-Induced Pulmonary Hypertension by Modulating Expression of Cyclin Dependent Kinase 6 (CDK6) in Pulmonary Smooth Muscle Cells
por: Sang, Hai-yan, et al.
Publicado: (2016)

Phosphorylation of mixed lineage kinase MLK3 by cyclin-dependent kinases CDK1 and CDK2 controls ovarian cancer cell division
por: Cedeno-Rosario, Luis, et al.
Publicado: (2022)

Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors
por: Sofi, Shazia, et al.
Publicado: (2022)

Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells
por: Marko, D, et al.
Publicado: (2001)

The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer
por: Zhou, Yubing, et al.
Publicado: (2016)

The M-phase specific hyperphosphorylation of Staufen2 involved the cyclin-dependent kinase CDK1
por: Beaujois, Rémy, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kokumm47j84n7vek1ovfi8fars